Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post‐CAR‐T‐cell therapy
Sign Up to like & getrecommendations! Published in 2025 at "British Journal of Haematology"
DOI: 10.1111/bjh.20266
Abstract: Efficacy of chimeric antigen receptor (CAR) T‐cell therapy hinges on CAR‐T potency, as well as on tumour traits and disease status. Potency assessment currently relies on post‐infusion in vivo growth; therefore, manufacturing metrics could provide… read more here.
Keywords: vivo; car; cell; post car ... See more keywords
CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-194162
Abstract: Background: Patients (pts) with (w/) relapsed and refractory (R/R) acute myeloid leukemia (AML) have a dismal prognosis. Chimeric antigen receptor T cell (CAR T) therapy for AML has been limited by lack of optimal surface… read more here.
Keywords: car; cell; expansion; post car ... See more keywords
Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-198920
Abstract: Introduction: Since 2020, Chimeric antigen receptor T-cell (CAR-T), namely Brexucabtagene autoleucel (Brexu-Cel), is approved for mantle cell lymphoma (MCL) patients in relapsed or refractory (RR) post BTK inhibitors (BTKi), based on significant complete and duration… read more here.
Keywords: post car; car; response; mantle cell ... See more keywords
Whole Body CD8+ T Cell PET Imaging in Patients with DLBCL before and during Anti-CD19 CAR T Cell Therapy
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-199474
Abstract: CAR T cell therapy (CART) has advanced the treatment of patients (pts) with refractory/relapsed diffuse large B-cell lymphoma (RR DLBCL), but long-term disease control eludes most recipients. Better clinical outcomes are associated with dense CD8+… read more here.
Keywords: cd8; car; cell; suvpeak ... See more keywords
Phenotype and functional state of endogenous T-cells support T-cell engager therapy in the post-CAR T therapy setting
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-3565
Abstract: Several new therapies have been approved for the treatment of B-cell NHL in the relapsed/refractory setting. CD3xCD20 bispecific antibodies and chimeric antigen receptor T-cell (CAR T) therapy are powerful immunotherapies that activate T-cells to kill… read more here.
Keywords: therapy; endogenous cells; car therapy; car ... See more keywords
CD19-CAR T cell therapy as a definitive consolidation in older adults with b-ALL in CR1 is safe and induces durable MRD- remission
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-443
Abstract: Introduction: Older adults with B-cell acute lymphoblastic leukemia (B-ALL) have dismal outcomes due to adverse-risk disease biology and poor tolerability of curative therapy. Low disease burden pre-lymphodepletion (LD) prior to chimeric antigen receptor T-cell therapy… read more here.
Keywords: therapy; car; cell; post car ... See more keywords
Overlap of post-CAR T HLH toxicity definitions and their prognostic significance in children and young adults with B-acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-4501
Abstract: Introduction: Hemophagocytic lymphohistiocytosis (HLH) toxicities are increasingly recognized following chimeric antigen receptor (CAR) T-cell therapies and are included on the FDA label of each commercial CAR product. Prior to the ASTCT immune effector cell-associated HLH-like… read more here.
Keywords: definition; tisa cel; car; post car ... See more keywords
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.
Sign Up to like & getrecommendations! Published in 2022 at "Blood advances"
DOI: 10.1182/bloodadvances.2022008240
Abstract: Most patients receiving CAR T-cell therapy (CAR-T) for aggressive B-cell lymphoma (B-NHL) will not experience a durable remission. There are several novel agents approved for the treatment relapsed, refractory aggressive B-NHL; however, it remains unclear… read more here.
Keywords: car; car failure; aggressive nhl; post car ... See more keywords